Collecting patient data through electronic PROs (ePROs) or electronic clinical outcome assessments (eCOAs) has been integral for patient centricity. These tools allow sponsors to meet patients where they are to gather real-time insights directly from the source, boosting patient retention and engagement. ePROs and eCOAs improve clinical trial outcomes with additional data points around a patient’s experience. However, the addition of consumer technologies that can collect ambient data points is poised to enhance outcomes even more, bringing treatments faster to those who need them most.
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of $43.5 billion, with a 71% year-on-year (YoY) increase of mega deals that were valued at $1 billion or more compared to Q1 2023, reveals GlobalData.
In today’s first-quarter 2024 financial results, Bayer reported a slight drop in sales amid its sweeping companywide restructuring that resulted in workforce reductions, while lowering its full-year earnings outlook.
The company announced that the FDA declined to approve the expanded use of its hepatitis B vaccine in patients undergoing hemodialysis, citing insufficient safety and effectiveness data.
Cytokinetics released data on aficamten, an oral small molecule inhibitor of cardiac myosin, showing it significantly boosted exercise capacity in patients with obstructive hypertrophic cardiomyopathy.
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy (semaglutide) provides cardiovascular benefits irrespective of starting weight and the amount of weight lost.
